Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Teva Pharmaceutical Industries ADR
(NY:
TEVA
)
17.95
-0.01 (-0.06%)
Official Closing Price
Updated: 7:00 PM EDT, Oct 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
3,605,733
Open
17.96
Bid (Size)
17.76 (1)
Ask (Size)
18.06 (1)
Prev. Close
17.96
Today's Range
17.73 - 18.02
52wk Range
8.055 - 19.08
Shares Outstanding
1,110,352,397
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Amicus Therapeutics Settles Patent Lawsuit Teva Pharmaceuticals Over Generic Version Of Its Rare Genetic Disorder Drug
October 17, 2024
Amicus Therapeutics enters a license agreement with Teva Pharmaceuticals resolving patent litigation over a generic version of Galafold. Teva may market its version starting in 2037, pending FDA...
Via
Benzinga
Topics
Intellectual Property
Lawsuit
Exposures
Financial
Intellectual Property
Legal
Teva Pays $450M To Resolve Alleged Kickback, Price-Fixing Schemes
October 11, 2024
Teva Pharmaceuticals will pay $450 million to resolve allegations of kickback schemes involving Medicare copays and price-fixing. This settlement is part of a broader crackdown on healthcare fraud...
Via
Benzinga
Topics
Fraud
Exposures
Legal
Performance
YTD
+68.23%
+68.23%
1 Month
+1.07%
+1.07%
3 Month
+5.71%
+5.71%
6 Month
+39.36%
+39.36%
1 Year
+121.06%
+121.06%
More News
Read More
Here's How Much $100 Invested In Teva Pharmaceutical Indus 5 Years Ago Would Be Worth Today
October 10, 2024
Via
Benzinga
Teva Prolia® (Denosumab) Biosimilar Candidate is Accepted for Review by U.S. FDA and EU EMA
October 08, 2024
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,400 Today
September 16, 2024
Via
Benzinga
Key Takeaways From Teva Pharmaceutical Indus Analyst Ratings
September 03, 2024
Via
Benzinga
Medicare Drug Price Negotiation Program Gets Final Guidance For Second Cycle, $1.5B Savings Expected
October 03, 2024
Via
Benzinga
Teva and mAbxience Expand Strategic Partnership to include an additional Oncology Biosimilar Candidate
October 03, 2024
From
Teva Pharmaceutical Industries Ltd; mAbxience
Via
GlobeNewswire
Teva Launches Generic Version Of Sandostatin In The US
October 01, 2024
Via
Benzinga
Teva Announces Launch of the First and Only Generic Version of Sandostatin® LAR Depot (octreotide acetate for injectable suspension), in the U.S.
October 01, 2024
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Teva to Host Conference Call to Discuss Third Quarter 2024 Financial Results at 8 a.m. ET on November 6, 2024
September 30, 2024
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
$1000 Invested In Teva Pharmaceutical Indus 5 Years Ago Would Be Worth This Much Today
September 30, 2024
Via
Benzinga
Corcept Therapeutics' Commercial Drug Korlym Sales Impress Despite Increased Competition, Analyst Boosts Price Forecast
September 30, 2024
Via
Benzinga
As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse
September 24, 2024
Via
FinancialNewsMedia
Exposures
Product Safety
As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse
September 24, 2024
From
FN Media Group LLC
Via
GlobeNewswire
Teva Announces Long Term Efficacy and Safety of Deutetrabenazine in European Patients with Debilitating Movement Disorder Tardive Dyskinesia
September 23, 2024
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable for Adult Patients Diagnosed with Schizophrenia
September 21, 2024
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
New Data Provide Treatment Insights into Options for Switching Adult Patients Diagnosed with Schizophrenia to UZEDY® (risperidone) Extended-Release Injectable Suspension from Perseris® (RBP-7000)
September 21, 2024
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Teva to Present at the Bank of America 2024 Global Healthcare Conference
September 11, 2024
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
UnitedHealth Follows Competitors, Replaces Humira with Lower-Cost Biosimilars
September 11, 2024
Via
Benzinga
Teva Announces $80M Settlement To Baltimore: City Continues Opioid Litigation Against Other Companies
September 10, 2024
Via
Benzinga
JP Morgan Shows Most Interest In Teva, Organon As Specialty Pharma Sector Exhibits Signs Of Stability
September 06, 2024
Via
Benzinga
Shortage Relief: More Takeda's Vyvanse For ADHD On the Way As US Ramps Up Production
September 06, 2024
Via
Benzinga
Organon Stock Sees Relative Strength Rating Rise To 91
August 27, 2024
Via
Investor's Business Daily
Teva to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
August 26, 2024
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.